Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4122 | UC-MSCs Wiki | 0.45 |
| drug2916 | Placebo Wiki | 0.04 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to investigate if a brief online-delivered cognitive-behavioral intervention can reduce the degree of dysfunctional worry related to the Covid-19 pandemic, compared to a wait-list control condition.
Description: A 7-item self-rated scale to assess symtom severity of worry. Total score ranging from 0 to 21. Effects will be expressed as the change from baseline to last post-treatment value (Week 0-Week 3) period. Effects will also be assessed at one month and one year post-treatment.
Measure: • Covid-19-adapted version of the self-rated Generalized Anxiety Disorder Scale-7 (GAD-7) Time: Basline (week 0), during treatment (week 1 and week 2), post treatment (week 3), at one-month after treatment and also one year follow up.Description: A 9-item self-rated scale to assess symtoms of depression.Total score ranging from 0 to 54.
Measure: Montgomery Åsberg Depression Rating Scale - Self report (MADRS-S) Time: Baseline (week 0), post treatment (week 3), at one-month after treatment and also one year follow up.Description: A 5-item self-rated scale adapted to measure impact of the Covid-19 pandemic on work and social functioning. Total score ranging from 0 to 40.
Measure: Adapted Covid-19 version of the Work and Social Adjustment Scale (WSAS) Time: Basline (week 0), during treatment (week 1 and week 2), post treatment (week 3), at one-month after treatment and also one year follow up.Description: A 7-item self-rated scale to asess severity of insomnia symtoms. Total score ranging from 0 to 28.
Measure: Insomnia Severity Index (ISI) Time: Baseline (week 0), post treatment (week 3), at one-month after treatment and also one year follow up.Description: A self-rated scale to assess Coronavirus/covid-19 health/exposure status, life changes, changes in daily behaviors, impact on emotions/worries, changes in media use past two weeks and changes in substance use due to coronavirus/covid-19 crisis. The scale has bees translated to Swedish and adopted to a Swedish context.
Measure: Adapted Swedish version of the CoRonavIruS Health Impact Survey (CRISIS) Time: Baseline (week 0), post treatment (week 3), at one-month after treatment and also one year follow up.Description: A 12-item self-rated scale to assess intolerance of uncertainty. Total score ranging from 12 to 60.
Measure: Intolerance of uncertainty Scale (IUS) Time: Baseline (week 0), post treatment (week 3), at one-month after treatment and also one year follow up.Description: A self-rated scale to assess treamtent satisfaction.
Measure: Patient Satisfaction Questionnaire (PSQ) Time: Post treatment (week 3)Description: A self-rated questionnaire with free text options to assess adverse events du to the intervention.
Measure: Adverse events (AE) Time: Post treatment (week 3)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports